Characteristics of Sexual Dysfunction in Patients With Lung Cancer (LUDICAS)

Fundación GECP

Status: Completed

Conditions: Sexual Dysfunction; Lung Cancer

Treatments: Drug: Systemic oncological treatment

Study type: Observational

Funder types: Other

Identifiers

NCT06018376

GECP 23/01_LUDICAS

Details and patient eligibility

About

The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.

Full description

It is planned to develop a study with a larger number of patients with lung cancer, including the population of Spain and Latin American countries to obtain a sample of more diverse and heterogeneous characteristics, with clinical, cultural, and sociodemographic differences. This will make it possible to obtain better and greater data and therefore define the clinical and treatment factors significantly associated with DS in these individuals and obtain a more complete vision of the reality of the problem.

The results of this research will make it possible to carry out interventions specifically directed at this population and to modify the oncological follow-up guidelines currently in force. Likewise, the information collected will serve as the basis for generating new protocols for a multidisciplinary approach, including the participation of psychology and specialists in urology, gynecology, and psychiatry.

The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.

Enrollment: 553 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 years and less than or equal to 70 years.
• Diagnosis of lung cancer stages IB to IV.
• Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images.
• ECOG ≤ 2

Exclusion criteria

• Patients with comorbidities (renal failure, cardiovascular diseases or similar) not controlled with corresponding medical management.
• Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.

Trial design

553 participants in 1 patient group

Observational Study Group

Description:

* Age greater than or equal to 18 years and less than or equal to 70 years. * Diagnosis of lung cancer stages IB to IV. * Having received systemic oncological treatment for at least 3 months * ECOG ≤ 2

Treatment:

Drug: Systemic oncological treatment